High dose melphalan

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, BioInvent International AB

Conditions

Multiple MyelomaMyeloma

Phase 1

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

TerminatedNCT02756728

BioInvent International ABMultiple Myeloma

Start: 2016-05-31End: 2016-12-31Updated: 2020-03-12

Phase 3

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

CompletedNCT01413178

M.D. Anderson Cancer CenterMyeloma

Start: 2011-09-30End: 2019-03-10Updated: 2020-04-21

Related Papers

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

2019-03-2259 citations

A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma

PLoS ONE2017-02-0351 citations

Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.

Journal of Clinical Oncology2014-05-201 citations